Institutional members access full text with Ovid®

Share this article on:

Single Dose of Fluoxetine Increases Muscle Activation in Chronic Stroke Patients

Berends, Hanneke Irene MSc*; Nijlant, Juliëtte M.M. MD*†; van Putten, Michel J.A.M. MD, PhD; Movig, Kris L.L. PhD§; IJzerman, Maarten J. PhD, PT*∥

doi: 10.1097/WNF.0b013e3181633482
Original Articles

Objectives: This pilot study explores the influence of a single dose of fluoxetine (20 mg) on the muscle activation patterns and functional ability of the muscles in the lower part of the arm in chronic stroke patients.

Methods: A crossover, placebo-controlled clinical trial was conducted in 10 patients. After administration of either a single dose of fluoxetine (20 mg) or a placebo, muscle activation of the lower arm was measured during maximum (isometric) force of the musculus flexor carpi radialis and musculus extensor carpi radialis. Delay times, grip strength, and Motricity Index were measured to assess functional ability.

Results: After fluoxetine intake, a significant increase in activation was found in both agonist and antagonist muscles of the paretic arm (P < 0.05). This increase did not influence the motor function.

Conclusions: In this pilot study, it was found that fluoxetine influences motor output in chronic stroke patients. Therefore, fluoxetine may influence motor recovery after stroke. Additional studies have to be conducted to explore the effects of fluoxetine on motor recovery after stroke.

*Roessingh Research and Development, Enschede; †Department of Rehabilitation, Ziekenhuisgroep Twente, Almelo; Departments of ‡Neurology and Clinical Neurophysiology and §Clinical Pharmacy, Medisch Spectrum Twente; ∥Biomedical Technological Institute; and Institute of Technical Medicine, University of Twente, Enschede, The Netherlands.

Address correspondence and reprint requests to Hanneke Irene Berends, MSc, Roessingh Research and Development, PO Box 310, 7500 AH Enschede, The Netherlands; E-mail:

This study was partly supported by Euregio; INTERREG III-A-program.

© 2009 Lippincott Williams & Wilkins, Inc.